Literature DB >> 1733548

Pharmacokinetics of ara-C and ara-U in plasma and CSF after high-dose administration of cytosine arabinoside.

L M DeAngelis1, W Kreis, K Chan, E Dantis, S Akerman.   

Abstract

Cytosine arabinoside (ara-C) and uracil arabinoside (ara-U) levels were measured in the plasma, cerebrospinal fluid (CSF), and urine of 10 patients exhibiting primary central nervous system lymphoma who received 31 infusions of high-dose ara-C (3 g/m2) as part of their treatment regimen. Peak plasma and CSF ara-C levels were 10.8 and 1.5 micrograms/ml, respectively. Ara-C was cleared more rapidly from plasma than from CSF. Ara-U appeared rapidly in both plasma and CSF, reaching a peak that was 10 times higher than the corresponding ara-C concentration (104 and 11.2 micrograms/ml, respectively). Only 4%-6% of the dose was excreted unchanged in the urine, but 63%-73% of it appeared as ara-U within the first 24 h. The presence of leptomeningeal lymphoma did not affect the CSF level of ara-C or ara-U.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1733548     DOI: 10.1007/bf00686248

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  21 in total

Review 1.  Primary CNS lymphoma: managing patients with spontaneous and AIDS-related disease.

Authors:  L M Deangelis; J Yahalom; M Rosenblum; J B Posner
Journal:  Oncology (Williston Park)       Date:  1987-08       Impact factor: 2.990

2.  Saturation of ara-CTP accumulation during high-dose ara-C therapy: pharmacologic rationale for intermediate-dose ara-C.

Authors:  W Plunkett; J O Liliemark; E Estey; M J Keating
Journal:  Semin Oncol       Date:  1987-06       Impact factor: 4.929

3.  Clinical pharmacology of 1-beta-d-arabinofuranosyl cytosine.

Authors:  D H Ho; E Frei
Journal:  Clin Pharmacol Ther       Date:  1971 Nov-Dec       Impact factor: 6.875

4.  Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections.

Authors:  W R Shapiro; D F Young; B M Mehta
Journal:  N Engl J Med       Date:  1975-07-24       Impact factor: 91.245

5.  Primary CNS lymphoma: combined treatment with chemotherapy and radiotherapy.

Authors:  L M DeAngelis; J Yahalom; M H Heinemann; C Cirrincione; H T Thaler; G Krol
Journal:  Neurology       Date:  1990-01       Impact factor: 9.910

6.  High-dose cytarabine in acute leukemia: toxicity and pharmacokinetics.

Authors:  Y Pommier; L Pochat; J P Marie; R A Zittoun
Journal:  Cancer Treat Rep       Date:  1983-04

7.  Pharmacokinetic studies of intermediate-to high-dose 1-beta-D-arabinofuranosylcytosine in children with acute leukemia and lymphoma.

Authors:  Y Takashima; K Matsuyama
Journal:  J Clin Pharmacol       Date:  1987-04       Impact factor: 3.126

8.  Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy.

Authors:  W Plunkett; J O Liliemark; T M Adams; B Nowak; E Estey; H Kantarjian; M J Keating
Journal:  Cancer Res       Date:  1987-06-01       Impact factor: 12.701

9.  Increasing incidence of primary brain lymphoma in the US.

Authors:  N L Eby; S Grufferman; C M Flannelly; S C Schold; F S Vogel; P C Burger
Journal:  Cancer       Date:  1988-12-01       Impact factor: 6.860

10.  A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology.

Authors:  A P Early; H D Preisler; H Slocum; Y M Rustum
Journal:  Cancer Res       Date:  1982-04       Impact factor: 12.701

View more
  14 in total

Review 1.  The Emerging Role of Cytidine Deaminase in Human Diseases: A New Opportunity for Therapy?

Authors:  Audrey Frances; Pierre Cordelier
Journal:  Mol Ther       Date:  2019-12-06       Impact factor: 11.454

2.  BST-236, a novel cytarabine prodrug for patients with acute leukemia unfit for standard induction: a phase 1/2a study.

Authors:  Tsila Zuckerman; Ron Ram; Luiza Akria; Maya Koren-Michowitz; Ron Hoffman; Israel Henig; Noa Lavi; Yishai Ofran; Netanel A Horowitz; Olga Nudelman; Sigal Tavor; Shay Yeganeh; Stela Gengrinovitch; Liat Flaishon; Shoshi Tessler; Ruth Ben Yakar; Jacob M Rowe
Journal:  Blood Adv       Date:  2019-11-26

3.  Identification of functional single nucleotide polymorphism haplotypes in the cytidine deaminase promoter.

Authors:  Sara M Fitzgerald; Rakesh K Goyal; William R A Osborne; Jennifer D Roy; John W Wilson; R E Ferrell
Journal:  Hum Genet       Date:  2006-01-31       Impact factor: 4.132

4.  Phenotypic analysis of 1-B-D-arabinofuranosylcytosine deamination in patients treated with high doses and correlation with response.

Authors:  W Kreis; M Lesser; D R Budman; Z Arlin; L DeAngelis; P Baskind; E J Feldman; S Akerman
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

5.  Inhibition of histone deacetylases 1 and 6 enhances cytarabine-induced apoptosis in pediatric acute myeloid leukemia cells.

Authors:  Xuelian Xu; Chengzhi Xie; Holly Edwards; Hui Zhou; Steven A Buck; Yubin Ge
Journal:  PLoS One       Date:  2011-02-16       Impact factor: 3.240

6.  Neurodegenerative central nervous system Langerhans cell histiocytosis and coincident hydrocephalus treated with vincristine/cytosine arabinoside.

Authors:  Carl E Allen; Ricardo Flores; Ronald Rauch; Robert Dauser; Jeffrey C Murray; Diane Puccetti; David A Hsu; Paul Sondel; Maxine Hetherington; Stan Goldman; Kenneth L McClain
Journal:  Pediatr Blood Cancer       Date:  2010-03       Impact factor: 3.167

7.  AraU accumulation in patients with renal insufficiency as a potential mechanism for cytarabine neurotoxicity.

Authors:  L H Lindner; H Ostermann; W Hiddemann; A Kiani; M Würfel; T Illmer; C Karsch; U Platzbecker; G Ehninger; E Schleyer
Journal:  Int J Hematol       Date:  2008-10-04       Impact factor: 2.490

8.  Cytosine arabinoside prodrug designed to bind plasma serum albumin for drug delivery.

Authors:  Wei Wei; Zhonggui He; Jincheng Yang; Mengchi Sun; Jin Sun
Journal:  Drug Deliv Transl Res       Date:  2018-10       Impact factor: 4.617

9.  Cytotoxic drug sensitivity of Epstein-Barr virus transformed lymphoblastoid B-cells.

Authors:  Laszlo Markasz; György Stuber; Emilie Flaberg; Asa Gustafsson Jernberg; Staffan Eksborg; Eva Olah; Henriette Skribek; Laszlo Szekely
Journal:  BMC Cancer       Date:  2006-11-13       Impact factor: 4.430

10.  Effects of cytarabine on activation of human T cells - cytarabine has concentration-dependent effects that are modulated both by valproic acid and all-trans retinoic acid.

Authors:  Elisabeth Ersvaer; Annette K Brenner; Kristin Vetås; Håkon Reikvam; Øystein Bruserud
Journal:  BMC Pharmacol Toxicol       Date:  2015-05-02       Impact factor: 2.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.